吉林敖东公告，预计2025年度净利润为22.65亿元～24.82亿元，同比增长46.00%～60.00%。2025年，预 计非经常性损益金额对净利润的影响金额约为1.96亿元（2024年同期为-2,151.12万元）。 ...

每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 （记者 曾健辉） 每经AI快讯，ST香雪1月30日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损约6.35 亿元~9.34亿元。上年同期归属于上市公司股东的净利润亏损约8.59亿元。业绩变动主要原因是，公司 存续的短期及长期借款金额较大，财务费用约2.5亿元。固定资产折旧、摊销影响约2亿元。对合并报表 范围内存在减值迹象的资产进行了减值测试，预计需对存货、在建工程、固定资产、开发支出等计提资 产减值合计约1.3亿元。对诉讼、逾期利息等营业外支出约2.2亿元。 ...

Industry Overview - The Chinese traditional medicine sector is experiencing performance pressure due to weak sales in pharmacies and hospitals since 2025, leading to a divergence in the performance of listed companies [3] - OTC leading enterprises show strong performance resilience, while the industry is undergoing a painful transition in its development model amid healthcare reform [3] - Future success will depend on diversified channels, strong brand power, and high clinical value, with long-term policies guiding the industry towards high-quality and standardized development [3] - The market for traditional Chinese medicine is rapidly growing, with new products driving growth momentum [3] - Continuous favorable measures from the supply, payment, and demand sides are promoting the prosperity and development of the traditional Chinese medicine industry [3] Company Overview - Panlong Pharmaceutical, a leading enterprise in the field of traditional Chinese medicine for rheumatology and orthopedics, has 25 production lines certified by the new national GMP, producing tablets and capsules [3] - The company has developed a strong product lineup, including the nationally exclusive patented product "Panlong Seven Tablets," covering 12 major functional categories and over 100 specifications [3] - The company is actively expanding its online sales channels for health products across six platforms, including JD.com, Taobao, Weimeng, WeChat Mini Programs, Video Number, and Douyin [4] - Panlong Pharmaceutical is expected to benefit from policy dividends, the accelerating trend of population aging, and consumption upgrades [5]

Group 1: Event Overview - The Shenzhen Stock Exchange held a special roadshow in Hong Kong titled "Investing in New Opportunities in China," featuring eight listed companies from the Shenzhen market [1] - The event aimed to showcase the investment value of high-quality assets in Shenzhen and the industrial upgrades of these companies to overseas asset management institutions [1] - Since 2023, the Shenzhen Stock Exchange has organized overseas roadshows covering 14 countries and regions, connecting over 2,000 foreign institutional investors [1] Group 2: Company Highlights - Juxing Technology operates 23 production bases globally, with over 95% of its revenue coming from overseas, making it a major supplier for top global retailers [7] - Yilian Network maintains a global market share of over 95% in SIP phones and ranks among the top five in video conferencing systems, benefiting from a dynamic order allocation mechanism [7] - Changying Precision is expanding its production bases in Vietnam and Mexico to meet the diversified supply chain needs of major clients like Apple and CATL [7] - Shenghong Technology is leading the market with advanced materials and technologies, focusing on AI-related products and sustainable development strategies [7][8] Group 3: Consumer Sector Insights - Yunnan Baiyao is projected to exceed 40 billion yuan in revenue in 2024, with a net profit of 4.75 billion yuan, showcasing a strong dividend policy and brand strength [8] - Salted Fish has established a closed-loop system for product development, achieving a rapid iteration cycle and a return on equity of 40.9%, attracting significant foreign investor interest [8] Group 4: Investor Sentiment and Future Outlook - Foreign investors remain optimistic about the Chinese stock market, anticipating a sustainable growth cycle driven by improving fundamentals and long-term growth potential [9] - The "14th Five-Year Plan" emphasizes increasing domestic consumption and technological self-reliance, which may lead to new growth opportunities in the consumer sector and for companies with strong R&D capabilities [9] - The Shenzhen Stock Exchange plans to enhance services for overseas investors and facilitate cross-border investment activities to support domestic and international economic circulation [9]

Core Viewpoint - The judicial system in Kunming, Yunnan Province, is actively supporting high-quality economic development by addressing the needs of three major economies through innovative legal services and solutions [1][2][3][4] Group 1: Judicial Support for Economic Recovery - The Kunming Intermediate People's Court successfully resolved a debt crisis for Yunnan Jiaotou Ecological Technology Co., Ltd., allowing the company to avoid delisting and protect the rights of 7037 small investors and 246 creditors, with a total debt of 1.976 billion yuan being resolved [2] - The court has established a legal service center in the industrial park to resolve disputes and has actively participated in events like the 9th China-South Asia Expo to support the exhibition economy [2] Group 2: Cross-Border Trade and Legal Services - The establishment of the "National Gate Court" in the Mohan port has facilitated the resolution of cross-border trade disputes, with the court handling 315 civil and commercial cases and providing legal consultations to over 1600 individuals in the past three years [3] - The Kunming court has implemented 18 measures to support the construction of the Mohan international port city and has established a judicial service network covering the port area [3] Group 3: Intellectual Property Protection and Innovation - The "demonstration judgment + invited mediation" model has expedited the resolution of 18 infringement cases in one day, saving companies significant costs in protecting their rights [4] - Over the past three years, Kunming courts have adjudicated 6721 intellectual property cases, including 740 related to new productive forces like biomedicine and digital economy, with six cases recognized as national typical cases [4]

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" introduces significant innovations, particularly in supporting pediatric and rare disease medications through market exclusivity periods, which is expected to stimulate investment in these areas by companies like Yiling Pharmaceutical [2][7]. Group 1: Drug Innovation and Market Exclusivity - The new regulations provide a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, contingent on the commitment to ensure drug supply [2]. - Yiling Pharmaceutical emphasizes innovation as a core driver of its development, establishing a research model based on clinical practice and traditional Chinese medicine theories [2][3]. - The company has 17 patented traditional Chinese medicine products on the market, with 12 included in the National Basic Medical Insurance Directory and 5 in the National Essential Medicines List [3]. Group 2: Research and Development Focus - Yiling Pharmaceutical plans to increase investment in pediatric and rare disease drug development following the implementation of the new regulations, with products like "Children's Lianhua Qingwen Granules" already in the application stage [3]. - The company has submitted new drug applications for several innovative traditional Chinese medicines and has five others in Phase II clinical trials [3]. Group 3: Quality Control and Safety - The new regulations impose stricter requirements on the production and sale of traditional Chinese medicine, necessitating improved quality control systems from source to end [4][6]. - Yiling Pharmaceutical has established a comprehensive quality management system based on Good Manufacturing Practice (GMP), focusing on full lifecycle quality control [5][6]. - The company has created 60 standardized traditional Chinese medicine cultivation bases across the country to ensure the quality and efficacy of its products [6]. Group 4: Future Directions - Yiling Pharmaceutical aims to enhance innovation investment, improve quality systems, promote internationalization, and strengthen talent development in response to the new regulations [7].

Group 1 - The company ST HuLuWa announced that as of the disclosure date, there are no guarantees provided to entities outside the consolidated financial statements [1] - The total external guarantee balance of the company and its subsidiaries is approximately 255 million yuan, accounting for 36.44% of the latest audited net assets [1] - The guarantee balance for the company's subsidiaries is about 245 million yuan, representing 35.01% of the latest audited net assets [1] Group 2 - The investigation into the "Jie Wo Rui" platform under Shui Bei Gold reveals a leverage of 40 times, leading to losses as gold prices rise [1] - The platform's owner claims to still be in Shenzhen, while investors express dissatisfaction with the proposed repayment plan, which offers only 20% of the principal [1]

（编辑 袁冠琳） 证券日报网讯 1月29日，广誉远在互动平台回答投资者提问时表示，国药堂、国医馆、博物馆是公司精 品业务的终端销售和文化展示渠道，采取经销模式，即将产品销售给合作伙伴，由其零售给消费者，不 存在"加盟费和盈利分成"。 ...

证券日报网讯1月29日，广誉远（600771）在互动平台回答投资者提问时表示，公司产品的出厂价属于 公司与合作伙伴的内部商业信息，不存在任何应披未披事项。 ...

Group 1 - The company is actively seeking partnerships with both domestic and international partners to promote the internationalization of traditional Chinese medicine [2] - The company's products, including Yuanhu Zhitong Droplets and Huangqi Danggui Capsules, have been registered and are being sold in Thailand [2]